Freedom-Meditech has been actively pursuing a qualified Series B Equity investment for its ClearPath DS-120 and I-SugarX product lines. The past six (6) months, Freedom-Meditech presented or attended over a dozen investor conferences starting in January with the prestigious JP Morgan Healthcare Conference in San Francisco. In April, the company engaged Xnergy Financial, LLC to target fundraising from family office funds. While we continue to seek an estimated $5M in capital ($3M equity, $2M debt), we are pleased to report that we secured over $750,000 in the first half of this year through our Series B convertible debt note facility. This is quite an accomplishment over a short period of time - just over ninety 90 days from the start of marketing to funds being closed. Since inception the company has now secured over $5M in investment capital.